rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1998-9-3
|
pubmed:abstractText |
Our purpose was to compare vaginally administered misoprostol (Cytotec) with intravenous oxytocin for labor induction in women with premature rupture of membranes beyond 36 weeks' gestation.
|
pubmed:commentsCorrections |
|
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/Americas,
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/Comparative Studies,
http://linkedlifedata.com/resource/pubmed/keyword/DELIVERY,
http://linkedlifedata.com/resource/pubmed/keyword/Developed Countries,
http://linkedlifedata.com/resource/pubmed/keyword/Endocrine System,
http://linkedlifedata.com/resource/pubmed/keyword/Fetal Membranes,
http://linkedlifedata.com/resource/pubmed/keyword/Fetus,
http://linkedlifedata.com/resource/pubmed/keyword/Hormones,
http://linkedlifedata.com/resource/pubmed/keyword/Misoprostol--administraction and...,
http://linkedlifedata.com/resource/pubmed/keyword/Misoprostol--therapeutic use,
http://linkedlifedata.com/resource/pubmed/keyword/North America,
http://linkedlifedata.com/resource/pubmed/keyword/Northern America,
http://linkedlifedata.com/resource/pubmed/keyword/OXYTOCIN,
http://linkedlifedata.com/resource/pubmed/keyword/PROSTAGLANDINS,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Pituitary Hormones,
http://linkedlifedata.com/resource/pubmed/keyword/Pregnancy,
http://linkedlifedata.com/resource/pubmed/keyword/Pregnancy Outcomes,
http://linkedlifedata.com/resource/pubmed/keyword/Premature Birth,
http://linkedlifedata.com/resource/pubmed/keyword/Prostaglandins, Synthetic,
http://linkedlifedata.com/resource/pubmed/keyword/Reproduction,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology,
http://linkedlifedata.com/resource/pubmed/keyword/Research Report,
http://linkedlifedata.com/resource/pubmed/keyword/Studies,
http://linkedlifedata.com/resource/pubmed/keyword/United States
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0002-9378
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
179
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
94-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:otherAbstract |
PIP: 197 of the 214 women who presented to a Los Angeles, California (US), hospital in 1995-97 with spontaneous rupture of the membranes beyond 36 weeks' gestation (mean, 38 weeks) volunteered for a comparative study of the effectiveness of vaginally administered misoprostol and oxytocin infusion. Induction was started a minimum of 6 hours after the spontaneous rupture of membranes. In 98 women, 25 mcg of misoprostol (Cytotec) was placed in the posterior vaginal fornix and, if uterine contraction frequency was deemed inadequate, the dose was repeated once in the next 6 hours (average, 1.3 dose). In the remaining 99 women, oxytocin was administered by infusion pump according to standard protocol, for a maximum dose of 22 mU/minute. 75 (75.8%) of misoprostol-treated women and 73 (74.5%) of oxytocin-treated subjects were delivered vaginally within 24 hours of induction initiation. The mean time from start of induction to vaginal delivery was 811.5 +or- 511.4 minutes in the misoprostol group and 747.0 +or- 448.0 minutes in oxytocin-treated subjects. 85 (85.9%) misoprostol-treated women and 82 (83.7%) oxytocin-treated subjects delivered vaginally. There were no significant differences between treatment groups in terms of tachysystole or hypertonus incidence or in the frequency of abnormal fetal heart rate tracings. Chorioamnionitis was diagnosed in 28 (28.6%) misoprostol-treated and 26 (26.3%) oxytocin-treated subjects. Neonatal outcomes were similar in both groups. Although misoprostol administration did not reduce the cesarean section delivery rate, its efficacy and safety were similar to oxytocin's, indicating this is a suitable regimen in women with premature rupture of membranes beyond 36 weeks' gestation.
|
pubmed:meshHeading |
pubmed-meshheading:9704771-Abortifacient Agents, Nonsteroidal,
pubmed-meshheading:9704771-Administration, Intravaginal,
pubmed-meshheading:9704771-Female,
pubmed-meshheading:9704771-Fetal Membranes, Premature Rupture,
pubmed-meshheading:9704771-Humans,
pubmed-meshheading:9704771-Labor, Induced,
pubmed-meshheading:9704771-Misoprostol,
pubmed-meshheading:9704771-Oxytocin,
pubmed-meshheading:9704771-Pregnancy,
pubmed-meshheading:9704771-Pregnancy Outcome,
pubmed-meshheading:9704771-Pregnancy Trimester, Third
|
pubmed:year |
1998
|
pubmed:articleTitle |
Induction of labor with misoprostol for premature rupture of membranes beyond thirty-six weeks' gestation.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Women's and Children's Hospital, University of Southern California School of Medicine, Los Angeles 90033, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|